Novel anticancer compounds induce apoptosis in melanoma cells
Uppoor G Bhat1, Patricia A Zipfel, Douglas S Tyler
1Department of Medicine, University of Illinois at Chicago, Chicago, Illinois 60612, USA.
Cell Cycle (Georgetown, Tex.)
|June 28, 2008
Summary
ARC and Siomycin A, novel anti-cancer drugs, show potent melanoma cell death induction. They are more effective than dacarbazine and may offer new melanoma treatment strategies.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- ARC (4-amino-6-hydrazino-7-beta-D-ribofuranosyl-7H-Pyrrolo[2,3-d]-pyrimidine-5-carboxamide) is a nucleoside analog and transcriptional inhibitor.
- Siomycin A is a thiazole antibiotic and a FoxM1 inhibitor.
- Both compounds have previously demonstrated apoptosis induction in various cancer cell lines.
Purpose of the Study:
- To characterize the anti-melanoma effects of ARC and Siomycin A.
- To compare their efficacy against the standard melanoma drug dacarbazine (DTIC).
- To investigate the role of Mcl-1 in mediating resistance and the potential synergy between ARC and Siomycin A.
Main Methods:
- Treatment of melanoma cell lines with ARC, Siomycin A, thiostrepton, and dacarbazine.
- Assessment of cell growth inhibition and apoptosis induction.
- Analysis of Mcl-1 overexpression effects on drug sensitivity.
- Evaluation of synergistic effects between ARC and Siomycin A.
Main Results:
- ARC and Siomycin A demonstrated potent inhibition of melanoma cell growth and induced cell death at low concentrations, outperforming dacarbazine.
- Overexpression of the antiapoptotic protein Mcl-1 conferred protection against apoptosis induced by these compounds.
- ARC and Siomycin A exhibited synergistic effects in inducing apoptosis in the DM833 melanoma cell line.
Conclusions:
- ARC and Siomycin A are highly effective in inhibiting melanoma cell growth and inducing apoptosis.
- These compounds may overcome resistance mechanisms mediated by Mcl-1.
- Their synergistic action suggests they target distinct anti-apoptotic pathways, highlighting their potential as novel anti-melanoma therapeutics.
Related Concept Videos
01:31The Intrinsic Apoptotic Pathway
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:17The Extrinsic Apoptotic Pathway
The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
01:30Apoptosis
Apoptosis is a combination of two Greek words, 'apo' and 'ptosis,' meaning separation and falling off, respectively. Hippocrates used this word to describe gangrene, which was caused due to bandaging of fractured bones. Apoptosis was distinguished from necrosis in 1970 when John Kerr reported observations of morphological changes occurring during apoptosis. During one experiment, he observed that the disruption of blood supply to the liver tissue resulted in a size reduction of the tissue.